Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

Recruiting in Palo Alto (17 mi)

+7 other locations

Age: 18 - 65

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Neuronetics

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and effectiveness of acute NeuroStar TMS therapy in women who have postpartum depression.

Eligibility Criteria

Inclusion Criteria

Female outpatients, 18 to 50 years of age.

Diagnosis of DSM-IV defined Major Depressive Disorder, single or recurrent episode, with current episode duration of at least 2 weeks.

Onset and duration of current illness within 6 months of live childbirth.

See 5 more

Treatment Details

Interventions

NeuroStar TMS Therapy (Transcranial Magnetic Stimulation)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Transcranial Magnetic Stimulation (TMS)Experimental Treatment1 Intervention

Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase. Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints.